The COVID-19 pandemic is highly disruptive to individuals, governments, and industries around the world. This paper takes a look at how COVID-19 could impact a range of stakeholders and components within the healthcare system. It also outlines implications and recommendations from the pharmaceutical / biotech industry’s perspective.
- Customer Landscape Impact / Implications for Biopharma
- Patients
- Healthcare Providers
- Healthcare Sites
- Treatment Patterns and Decision-Making
- Drug Development and Commercialization Impact / Implications for Biopharma
- Clinical Trials / Data Generation
- Manufacturing and Supply Chain
- Regulatory / Reimbursement / Access
- Pharma Workforce Impact
- Individual Level
- Team / Functional Group Level
- Corporate Level